Alpha Teknova Inc
TKNO4.460USD
-0.190-4.09%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
238.72MMarket Cap
LossP/E TTM
More Details of Alpha Teknova Inc Company
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary product categories, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. It supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and others, with catalog and custom, made-to-order products.
Alpha Teknova Inc Info
Ticker SymbolTKNO
Company nameAlpha Teknova Inc
IPO dateJun 25, 2021
CEOGunstream (Stephen)
Number of employees173
Security typeOrdinary Share
Fiscal year-endJun 25
Address2451 Bert Drive
CityHOLLISTER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code95023
Phone18316371100
Websitehttps://www.teknova.com/
Ticker SymbolTKNO
IPO dateJun 25, 2021
CEOGunstream (Stephen)
Company Executives of Alpha Teknova Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Irene Davis
Ms. Irene Davis
Director
Director
1.69M
--
Mr. Stephen Gunstream
Mr. Stephen Gunstream
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.50K
+13.39%
Mr. Alexander Vos
Mr. Alexander Vos
Independent Director
Independent Director
126.72K
+74.98%
Mr. Damon Terrill
Mr. Damon Terrill
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
41.03K
--
Ms. Martha J. Demski
Ms. Martha J. Demski
Independent Director
Independent Director
25.07K
-24.19%
Dr. Paul D. Grossman
Dr. Paul D. Grossman
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
9.21K
--
Alex Herzick
Alex Herzick
Director
Director
--
--
Ms. Brett M. Robertson
Ms. Brett M. Robertson
Independent Director
Independent Director
--
--
Mr. J. Matthew Mackowski
Mr. J. Matthew Mackowski
Director
Director
--
--
Mr. Matthew C. Lowell
Mr. Matthew C. Lowell
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Irene Davis
Ms. Irene Davis
Director
Director
1.69M
--
Mr. Stephen Gunstream
Mr. Stephen Gunstream
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.50K
+13.39%
Mr. Alexander Vos
Mr. Alexander Vos
Independent Director
Independent Director
126.72K
+74.98%
Mr. Damon Terrill
Mr. Damon Terrill
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
41.03K
--
Ms. Martha J. Demski
Ms. Martha J. Demski
Independent Director
Independent Director
25.07K
-24.19%
Dr. Paul D. Grossman
Dr. Paul D. Grossman
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
9.21K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Lab Essentials
7.79M
75.75%
Clinical Solutions
2.06M
20.03%
Other
435.00K
4.23%
By RegionUSD
Name
Revenue
Proportion
United States
9.78M
95.04%
International
510.00K
4.96%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Lab Essentials
7.79M
75.75%
Clinical Solutions
2.06M
20.03%
Other
435.00K
4.23%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Telegraph Hill Partners
70.46%
Davis (Ted)
3.53%
Davis (Irene)
3.15%
UBS Financial Services, Inc.
2.80%
Balyasny Asset Management LP
1.84%
Other
18.21%
Shareholders
Shareholders
Proportion
Telegraph Hill Partners
70.46%
Davis (Ted)
3.53%
Davis (Irene)
3.15%
UBS Financial Services, Inc.
2.80%
Balyasny Asset Management LP
1.84%
Other
18.21%
Shareholder Types
Shareholders
Proportion
Private Equity
70.46%
Individual Investor
10.71%
Investment Advisor
6.44%
Investment Advisor/Hedge Fund
4.68%
Hedge Fund
2.15%
Research Firm
0.65%
Bank and Trust
0.08%
Pension Fund
0.04%
Other
4.80%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
143
45.32M
84.68%
-1.67M
2025Q2
134
49.86M
93.29%
-910.00K
2025Q1
159
49.02M
94.72%
+9.59M
2024Q4
142
49.19M
92.33%
+11.09M
2024Q3
142
47.90M
89.93%
+8.81M
2024Q2
140
36.69M
87.73%
-3.53M
2024Q1
145
36.60M
90.14%
-2.50M
2023Q4
149
35.47M
91.35%
-3.28M
2023Q3
155
35.09M
90.51%
+4.53M
2023Q2
176
26.14M
92.65%
-5.67M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Telegraph Hill Partners
37.72M
70.48%
--
--
Apr 22, 2025
Davis (Ted)
1.89M
3.53%
--
--
Apr 22, 2025
Davis (Irene)
1.69M
3.15%
--
--
Apr 22, 2025
UBS Financial Services, Inc.
1.58M
2.96%
+424.17K
+36.58%
Jun 30, 2025
Balyasny Asset Management LP
1.00M
1.87%
+163.53K
+19.54%
Jun 30, 2025
Roubaix Capital, LLC
439.94K
0.82%
+439.94K
--
Jun 30, 2025
Mackowski J Matthew
820.81K
1.53%
--
--
Apr 22, 2025
Lowell (Matthew)
820.81K
1.53%
+701.77K
+589.51%
Apr 22, 2025
The Vanguard Group, Inc.
652.18K
1.22%
+78.74K
+13.73%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
615.90K
1.15%
+480.11K
+353.57%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Nanotechnology ETF
0.52%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
View more
ProShares Nanotechnology ETF
Proportion0.52%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Biotechnology ETF
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Alpha Teknova Inc?
The top five shareholders of Alpha Teknova Inc are:
Telegraph Hill Partners holds 37.72M shares, accounting for 70.48% of the total shares.
Davis (Ted) holds 1.89M shares, accounting for 3.53% of the total shares.
Davis (Irene) holds 1.69M shares, accounting for 3.15% of the total shares.
UBS Financial Services, Inc. holds 1.58M shares, accounting for 2.96% of the total shares.
Balyasny Asset Management LP holds 1.00M shares, accounting for 1.87% of the total shares.
Telegraph Hill Partners holds 37.72M shares, accounting for 70.48% of the total shares.
Davis (Ted) holds 1.89M shares, accounting for 3.53% of the total shares.
Davis (Irene) holds 1.69M shares, accounting for 3.15% of the total shares.
UBS Financial Services, Inc. holds 1.58M shares, accounting for 2.96% of the total shares.
Balyasny Asset Management LP holds 1.00M shares, accounting for 1.87% of the total shares.
What are the top three shareholder types of Alpha Teknova Inc?
The top three shareholder types of Alpha Teknova Inc are:
Telegraph Hill Partners
Davis (Ted)
Davis (Irene)
Telegraph Hill Partners
Davis (Ted)
Davis (Irene)
How many institutions hold shares of Alpha Teknova Inc (TKNO)?
As of 2025Q3, 143 institutions hold shares of Alpha Teknova Inc, with a combined market value of approximately 45.32M, accounting for 84.68% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.61%.
What is the biggest source of revenue for Alpha Teknova Inc?
In FY2025Q2, the Lab Essentials business generated the highest revenue for Alpha Teknova Inc, amounting to 7.79M and accounting for 75.75% of total revenue.
